HSPA5 and acute myeloid leukemia: Following this concept, Hebbar et al. have developed a strategy to target GRP78 in AML cells with anti-GRP78 CAR-T cells that have been treated with dasatinib during the manufacturing process, thus blocking their differentiation and maintaining a more naïve-like phenotype.